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ing,	with	 estimates	 of	 key	QoL	 and	 cost	 data	 often	 based	on	 small	 data	 sets	 and	
without	comparison	to	population	norms.	Therefore,	the	clinical	impact	of	mild	hae‐
mophilia	may	be	under‐represented	and	unmet	needs	may	remain	unaddressed.	As	
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1  | INTRODUC TION
Haemophilia	 A	 (HA)	 is	 an	 X‐linked	 bleeding	 disorder	 caused	 by	
a	 deficiency	 of	 blood	 coagulation	 factor	 VIII	 (FVIII),	 occurring	 in	
approximately	1	out	of	every	5000	male	 live	births.1	HA	can	be	a	
life‐threatening	 condition	 that	 requires	 lifelong	monitoring	 and/or	
treatment.	 Management	 strategies	 include	 the	 use	 of	 plasma‐de‐













but	may	still	experience	 limitations	 in	daily	activities	and	 impacts	of	






2  | MATERIAL S AND METHODS




mild	HA	 in	 adults.	 This	 review	was	 conducted	 and	 reported	 ac‐




of	age	or	older)	with	mild	HA.	We	were	unable	 to	 find	any	 recent	
summary	of	the	literature	in	this	population,	and	the	clinical	picture	







spectively	defined	 in	order	 to	exclude	 studies	of	 insufficient	 sam‐
ple	size,	for	which	outcomes	may	not	be	generalizable	as	they	may	
focus	on	 reports	 of	 unusual	 cases.	Outcomes	of	 interest	 included	
bleeding	events	(any	event	as	defined	or	described	by	authors),	QoL,	
joint	pain,	function/disability,	health	care	utilization	and	cost	(direct	
health	 care	 cost	 and/or	 indirect	 societal	 cost).	As	our	 goal	was	 to	
assess	the	burden	of	disease,	no	specific	intervention	or	comparison	
was	required	in	the	included	studies.
2.1 | Data sources and search strategies
A	comprehensive	search	of	English‐language	biomedical	literature	was	
conducted.	We	 searched	 electronic	 repositories	 including	 PubMed/
MEDLINE,	the	Cochrane	Library	and	EMBASE	for	all	available	dates	
up	to	the	search	cut‐off	date	of	31	December	2017.	The	search	terms	







tions	downloaded	 from	 the	 search	and	each	 level	of	 screening	 in‐
volved	up	to	two	reviewers.	Level	I	screening	was	conducted	on	the	
title	and	abstract	of	each	citation	to	identify	potentially	eligible	stud‐







































CEBM)	Levels	of	Evidence.10	 Industry	 sponsorship	was	captured	 for	
each	included	study,	based	on	author	disclosures	or	affiliations.
2.4 | Synthesis of results
We	 planned	 to	 conduct	 a	meta‐analysis	 if	 sufficient	 comparable	 data	
were	found	for	a	primary	or	secondary	outcome.	Differences	in	author	
definitions	of	 the	primary	 endpoint,	 the	 rate	of	 bleeding	 events,	were	
available.	These	were	captured	and	reviewed	for	comparability	(eg	only	
bleeds	 requiring	 treatment,	only	 spontaneous	bleeds	unrelated	 to	 sur‐
gical	 or	 dental	 procedures,	 any	bleeding	 event).	Where	data	were	 too	
sparse	or	too	heterogeneous	to	be	combined	across	studies,	descriptive	








were	obtained	 in	 full	 text	 for	 review	 (Figure	1).	Application	of	eligi‐
bility	 criteria	 resulted	 in	 17	 included	 studies,	 comprising	 20	 pub‐
lications	 due	 to	 separate	 reports	 on	 the	 same	or	 overlapping	 study	
populations.3,8,11‐28	The	primary	reasons	for	study	exclusion	were	that	
patients	 with	 haemophilia	 were	 not	 separated	 by	 severity	 (or	 only	








tion	 in	all	 cases.	The	 total	number	of	haemophilia	patients	 (all	 ages,	






FVIII,11,13,27	except	 in	one	study	 reported	as	a	meeting	abstract,	 for	
which	long‐term	use	of	FVIII	concentrate	was	required.18
3.3 | Risk of bias
Most	evidence	was	Oxford	Level	of	Evidence	 IB	or	 IIB,	 consisting	
of	prospective	or	retrospective	cohort	studies,	in	many	cases	from	
a	 single	 centre	 (Table	 1).	No	 randomized	 controlled	 trials	meeting	
inclusion	 criteria	 were	 identified.	 The	 risk	 of	 selective	 reporting/
outcome	availability	bias	was	high,	as	mild	HA	adults	were	typically	
a	subset	of	the	entire	study	population,	and	not	all	outcomes	were	
F I G U R E  1  Study	attrition
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Bleeding	 events	 in	 mild	 HA,	 such	 as	 joint	 bleeds	 or	 cerebral	
bleeds,	 may	 not	 be	 readily	 apparent.	 One	 study	 used	 cerebral	




Joint	 pain	 and	 damage	 resulting	 from	 subclinical	 joint	 bleeds	may	
also	be	problematic	in	mild	HA.	Joint	score	data,	like	data	for	bleed‐
ing	 events,	 were	 not	 reported	 in	 a	 standard	 way	 across	 studies	
(Table	3).	In	a	small	cross‐sectional	survey	study	from	1996,	20%	of	
mild	HA	patients	age	16	or	older	experienced	moderate	or	severe	
pain	 in	 the	 previous	 year,	with	 pain	 and	 disability	 increasing	with	
age.22	Another	study	comparing	mild	HA	adults	with	age‐matched	





Patient‐reported	 outcomes	 were	 available	 in	 three	 studies,	 all	
of	 which	 were	 published	 in	 the	 past	 10	 years	 (Figure	 2).	 Each	
study	 used	 a	 different	 QoL	 instrument:	 the	 SF‐36,26	 SF‐123 and 
HAEMO‐QoL‐A.18	 SF‐36	general	 health	was	 lower	 for	mild	HA	vs	
age‐matched	 healthy	 controls	 in	 a	Canadian	 cohort	 (58.1	 vs	 70.8,	
P	<	0.05,	n	=	47).26	No	other	studies	reported	QoL	in	mild	HA	adults	
compared	to	healthy	controls	or	population	norms.
In	 a	 prospective	 US	 study,	 SF‐12	 physical	 component	 sum‐
mary	was	higher	(better	QoL)	for	mild	HA	compared	to	severe	HA	
(P	=	0.014,	n	=	42),	while	mental	component	summary	was	not	sig‐












































Year	of	publication   
1996‐2007b 2 56
2008‐2017 15 3157
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Quantifying	 outcomes	 for	 adult	 patients	with	mild	HA	 remain	
challenging,	with	estimates	of	 key	QoL	and	cost	data	often	based	





































































































treatment	 goals	 in	 haemophilia	 were	 FVIII	 trough	 levels	 of	 >1%,	
to	 prevent	 major	 bleeding.	With	 the	 advent	 of	 extended	 half‐life	
FVIII	 concentrates	 and	 novel	 non‐replacement	 therapies,	 and	 the	





of mild HA 
patients
Mean (SD) or Median (range)
Joint score (name of 
scale)
Pain or overall severity 
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current	best	practices	 for	 systematic	 literature	 review.	Limitations	
relate	 primarily	 to	 the	 availability	 and	 comparability	 of	 published	
evidence.	Data	 on	mild	HA	 adults	 are	 frequently	 aggregated	with	
moderate	HA,	mild	haemophilia	B	and/or	mild	HA	paediatric	patients	
in	the	published	literature.	Despite	our	efforts	to	extract	clinical	and	
























data	 from	 adult	 patients	 with	mild	 HA	 are	 frequently	 aggregated	
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